2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1742

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1732

Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1466

Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1399

Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1670

Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1015

Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1171

Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1632

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1148

Examining Five Year Lupus Retention in Care in an Academic Cohort

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1035

Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1745

Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1031

Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1110

Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study

Health Services Research Poster II – ACR/ARP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].